Low Molecular Weight Heparin in Pregnancies With Unexplained Stillbirths

Second Generation Low Molecular Weight Heparin (Bemiparin) as a Prophylactic for Management of Subsequent Pregnancy After an Unexplained Stillbirth: A Clinical Comparative Study

Status

Completed

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03601338

Enrollment

140

Registered

2018-07-26

Start date

2015-08-01

Completion date

2018-12-06

Last updated

2018-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unexplained Stillbirth

Keywords

Unexplained stillbirth, Low molecular Weight Heparin, Umbilical artery, Doppler Ultrasound, Antenatal care

Brief summary

Bemiparin for pregnant women with abnormal umbilical artery Doppler ultrasound

Detailed description

152 women with history of unexplained stillbirths were identified , umbilical arty Doppler ultrasound was conducted for them at 20-22 weeks gestation . they were divided into two group , group one are those with abnormal resistant index (= or more than 0.6) thy received Bemiparin 2500 IU subcutaneously daily up to 24 hours before delivery . Group 2 with normal umbilical artery resistant index received no any interventions just routine antenatal follow up .

Interventions

DRUGBemiparin

second generation low molecular weight Heparin

OTHERmultivitamins and routine antenatal follow up

multivitamins and routine antenatal follow up

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Intervention model description

pregnant women with history of unexplained fetal death

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 44 Years

Healthy volunteers

Yes

Inclusion criteria

* Second pregnancy after previous unexplained fetal death * Singleton pregnancy * No any medical disorders during pregnancy like diabetes or Systemic Lupus Erythematosus * Normally located placenta * No congenital fetal anomalies * Patient accept to participate

Exclusion criteria

* Confirmed thrombophilia * Twin pregnancies * Refused to participate

Design outcomes

Primary

Measure	Time frame	Description
Stillbirth	after 20 weeks gestation to the delivery of fetus	Intrauterine fetal death
Early neonatal death	First week of life	Death of newborn
Low birth weight	first hour of life	New borne with birth weight less than 5th percentile in kilogram

Secondary

Measure	Time frame	Description
Preterm labor	20-37 weeks	delivery of the fetus before 37 weeks gestation
Pre-eclampsia	20-41 week gestation	High blood pressure with protein urea
major abruptio placenta	20-41 week gestation	Antepartum hemorrhage

Countries

Iraq

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026